TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00884546
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule, Oral, Once a week, 6 months
Study: NCT00884546
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Powder, IV, On days 1, 4, 8, 11, 6 months
Study: NCT02746991
Drug: Sham Injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04312061
Drug: oral tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
Study: NCT00669591
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
Study: NCT01988649
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of intranasal Oxytocin
Study: NCT01309581
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 1-2 mg/kg IV as indicated for ECT
Study: NCT01309581
Drug: Methohexital
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital 1 mg/kg IV as indicated for ECT
Study: NCT02183792
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02183792
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003368
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04072328
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
Study: NCT04072328
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam with propofol
Study: NCT01203306
Drug: bevacizumab + octreotide LAR + capecitabine
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
Study: NCT01066546
Drug: Dimebon tablet for oral administration
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study
Study: NCT01581918
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
Study: NCT02709304
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
Study: NCT02709304
Drug: standard gel
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
Study: NCT03379051
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCL-2 Inhibitor
Study: NCT03379051
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3K-Delta Inhibitor
Study: NCT03379051
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
Study: NCT01676558
Drug: 131I-rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01873326
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01873326
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914158
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01873326
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914158
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914158
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01873326
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01873326
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01873326
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02060955
Drug: Bevacizumab/Irinotecan
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
Study: NCT03649243
Drug: Propolis spray
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
Study: NCT01077986
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered weekly, starting at day 8.
Study: NCT01077986
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be administered daily, starting on day 1.
Study: NCT02079506
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03953001
Drug: Topical Anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% Benzocaine gel was applied on the area of infiltration
Study: NCT00470223
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00470223
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00470223
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02014831
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study: NCT00596336
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
Study: NCT00654056
Drug: Actrapid (human insulin)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
Study: NCT03083067
Drug: Budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
Study: NCT03083067
Drug: tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
Study: NCT00002446
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002446
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03829852
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment was performed based on physician's discretion
Study: NCT00779233
Drug: Zidovudine tablets 300 mg
Normalized name: zidovudine Oral Tablet
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01477268
Drug: Zoloft (antidepressant)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zoloft 50-200 mg po od x 12 weeks
Study: NCT01121991
Drug: Recombinant Human-Luteinizing Hormone (Luveris)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
Study: NCT02670109
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg/m2, IV, in 3 hours, during day -4
Study: NCT02670109
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1400/m2, IV, in 1 hour, during day -3
Study: NCT02670109
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16mg/kg, Oral, during day -4
Study: NCT00902473
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25mg tablets
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
Study: NCT02848794
Drug: Apatinib and Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
Study: NCT00409838
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Study: NCT00409838
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, intravenous, 10 mg/kg, every 28 days
Study: NCT02055976
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg Q14D SC for 16 week
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg Q14D SC for 16 week
Study: NCT02055976
Drug: Bococizumab (PF-04950615;RN316)
Normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg Q14D SC for 16 week
Study: NCT03771313
Drug: Ceftaroline
Normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
Study: NCT02317783
Drug: [18F]Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brain scan with imaging tracer that binds to amyloid plaques
Study: NCT02365740
Drug: Insulin single bolus
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
Study: NCT02365740
Drug: Insulin double-wave bolus
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-prandial insulin fractioned into a double-wave bolus
Study: NCT05021666
Drug: PB 718
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose in the next group will be determined following a review of data from the previous group
Study: NCT02962401
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1
Study: NCT02962401
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment
Study: NCT00684866
Drug: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Study: NCT00682292
Drug: Thymoglobulin (ATG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
Study: NCT00682292
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
Study: NCT02022592
Drug: Lormetazepam
Normalized name: lormetazepam
DrugBank: Lormetazepam (DB13872)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02022592
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02317783
Drug: [18F]fluoro-2-deoxy-D-glucose (FDG)
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
Study: NCT00890396
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.
Study: NCT00684866
Drug: Racemic Albuterol followed by levalbuterol HFA MDI
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Study: NCT00633477
Drug: Resatorvid
Normalized name: Resatorvid
DrugBank: Resatorvid (DB05943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
Study: NCT02022059
Drug: Lidocaine = group A
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
Study: NCT01576029
Drug: CABAZITAXEL (XRP6258)
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT01576029
Drug: DOCETAXEL (XRP6976)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT00100698
Drug: recombinant human growth hormone
Normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
Study: NCT04337879
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
Study: NCT04337879
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
Study: NCT04337879
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
Study: NCT01392079
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
Study: NCT00313742
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00313742
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02142751
Drug: Fosfomycin sodium intravenous
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4g every 6 hours iv (60 min infusion)
Study: NCT02142751
Drug: Meropenem intravenous
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
Study: NCT00525954
Drug: A-002
Normalized name: CENPLACEL-L COMPONENT OF PDA-002
DrugBank: Cenplacel-L (DB19188)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766050
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01766050
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01766050
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01766050
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02649413
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
Study: NCT01472510
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Study: NCT01472510
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Study: NCT04093895
Drug: PerioSept(r)
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing followed by 3% PerioSept(r) administration
Study: NCT01571466
Drug: Vaccination
Normalized name: Multi-peptide vaccination
DrugBank: CoVac-1 (DB16429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16
Study: NCT02718079
Drug: Prophylactic Antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02718079
Drug: N-acetyl-L-cysteine
Normalized name: N-acetyl-L-cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03525444
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received IVA orally once daily in the evening
Study: NCT02906514
Drug: Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mL used for cardiopulmonary bypass priming
Study: NCT02906514
Drug: Sodium Chloride 0.9% (Fresenius)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mL used for cardiopulmonary bypass priming